Skip to content

Gomdori Medical

Evidence-Based Medical Education by gomdori, MD

MENU
  • Home
  • Gastroenterology
  • Procedures
  • Critical Care
  • More Specialties
    • Cardiovascular Medicine
    • Respiratory Medicine
    • Nephrology & Renal Care
    • Hematology
    • Oncology
    • Endocrinology
    • Allergy & Immunology
    • Infectious Diseases
    • Rheumatology
  • Tools
  • About gomdori Medical
  • Conference News
  • Clinical Library
Home » Community-Acquired Pneumonia — Diagnosis and Evidence-Based Treatment

Community-Acquired Pneumonia — Diagnosis and Evidence-Based Treatment

Posted on April 4, 2026November 12, 2026 by Gomdori
gomdori Medical · Clinical Guideline
Community-Acquired Pneumonia — Diagnosis and Evidence-Based Treatment
Clinical Guideline gomdorimedical.com
Home › Guidelines › Community-Acquired Pneumonia — Diagnosis and Evidence-Based Treatment
gomdori Medical
Clinical Guideline

Community-Acquired Pneumonia — Diagnosis and Evidence-Based Treatment

April 4, 2026 gomdori 18 min read ATS / IDSA Consensus
Referenced Clinical Guidelines
IDSA
Infectious Diseases Society of America
Practice guidelines for infectious diseases
CDC
Centers for Disease Control and Prevention
Public-health guidance and clinical recommendations
Executive Summary

Community-acquired pneumonia remains a leading cause of infectious disease mortality worldwide. Risk-stratify all patients using CURB-65 or PSI/PORT scoring, together with clinical judgment, to decide between outpatient and inpatient care; these scores were not designed to select the level of care for a hospitalized patient, so the choice between the general ward and the intensive care unit follows the ATS/IDSA severity criteria and clinical judgment. For outpatient management, initiate amoxicillin 1 g PO TID or doxycycline 100 mg PO BID as monotherapy in healthy adults without comorbidities, and add a macrolide for those with risk factors. Hospitalized patients with non-severe CAP require combination therapy with ceftriaxone 1–2 g IV daily plus azithromycin 500 mg IV/PO daily, or monotherapy with a respiratory fluoroquinolone. Assess clinical response at 48–72 hours, transition to oral therapy once hemodynamically stable, and target a total antibiotic duration of 5–7 days guided by clinical improvement and procalcitonin trends.

1.5M
US Hospitalizations / Year
85%
Outpatient Cure Rate
23%
ICU Admission Rate
10–12%
Inpatient Mortality
Contents
  1. Pathophysiology
    • Typical vs. atypical pathogens
    • Alveolar inflammatory cascade
  2. Diagnostic Protocol
    • CURB-65 & PSI/PORT scoring
    • Imaging & microbiologic workup
  3. Treatment Algorithm
    • Outpatient, inpatient, ICU tiers
    • Special populations & interactions
  4. Monitoring & Surveillance
  5. Clinical Commentary
  6. Practice Insights
    • What tends to drive CAP decisions at the bedside
  7. FAQ
1

Pathophysiology

Community-acquired pneumonia develops when pathogenic microorganisms overwhelm the host pulmonary defense mechanisms and establish infection within the lower respiratory tract. The primary route of inoculation is microaspiration of oropharyngeal secretions colonized with potential pathogens, though direct inhalation of aerosolized droplets predominates for atypical organisms such as Legionella pneumophila and respiratory viruses. Once organisms reach the terminal bronchioles and alveoli, the innate immune response mounts a vigorous neutrophilic inflammatory cascade that, while essential for pathogen clearance, simultaneously causes collateral alveolar damage, exudative fluid accumulation, and impaired gas exchange.

Core Mechanism
Microbial invasion of the alveolar epithelium triggers alveolar macrophage activation, toll-like receptor signaling (TLR-2, TLR-4), and massive neutrophil recruitment via IL-8 and CXCL-1, leading to exudative consolidation and ventilation-perfusion mismatch
Key Pathway
NF-kB-mediated cytokine release (TNF-alpha, IL-1-beta, IL-6) drives systemic inflammatory response; complement activation (C3a, C5a) enhances opsonization and leukocyte chemotaxis into the alveolar space
Genetic Factors
Polymorphisms in mannose-binding lectin (MBL2), surfactant proteins SP-A and SP-D, TLR-4 (Asp299Gly), and FCGR2A influence susceptibility to pneumococcal disease and severity of illness
Risk Factors
MODIFIABLE: tobacco smoking (3-fold risk), alcohol misuse, poor oral hygiene, immunosuppressive medications | NON-MODIFIABLE: age over 65, chronic lung disease (COPD, asthma, bronchiectasis), diabetes mellitus, congestive heart failure, prior splenectomy
Biomarkers
Procalcitonin (PCT) greater than 0.25 ng/mL suggests bacterial etiology; C-reactive protein (CRP) greater than 100 mg/L correlates with severe disease; lactate greater than 2 mmol/L indicates tissue hypoperfusion and sepsis risk

The pathophysiologic sequence begins when aspirated or inhaled organisms adhere to the alveolar epithelium through specific adhesins such as pneumococcal phosphorylcholine and choline-binding proteins. This triggers resident alveolar macrophages to recognize pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors, initiating a cytokine cascade that recruits neutrophils from the pulmonary capillary bed. Neutrophil degranulation releases elastase, reactive oxygen species, and matrix metalloproteinases that destroy invading organisms but simultaneously damage the alveolocapillary membrane. The resulting increase in capillary permeability allows protein-rich edema fluid, fibrin, red blood cells, and inflammatory cells to flood the alveolar spaces, producing the characteristic radiographic consolidation. Surfactant dysfunction occurs as type II pneumocyte injury reduces production and inflammatory exudate inactivates existing surfactant, promoting atelectasis and further worsening ventilation-perfusion mismatch. In severe cases, bilateral alveolar damage can progress to acute respiratory distress syndrome. Streptococcus pneumoniae remains the most frequently identified pathogen, followed by Haemophilus influenzae and Moraxella catarrhalis among typical bacteria. Atypical pathogens including Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila lack a classical cell wall, render Gram stain unhelpful, and require intracellular-active antibiotics for eradication. Respiratory viruses including influenza, SARS-CoV-2, and respiratory syncytial virus may cause primary viral pneumonia or predispose to secondary bacterial superinfection.

CAP Pathophysiology Flowchart Flowchart illustrating the stepwise pathophysiologic cascade of community-acquired pneumonia from initial pathogen entry through alveolar invasion, inflammatory response, consolidation, and clinical presentation with impaired gas exchange. Pathogen Inhalation / Aspiration Alveolar Epithelial Adhesion PAMPs activate TLR-2/4 on macrophages Neutrophilic Inflammatory Cascade NF-kB, TNF-alpha, IL-1-beta, IL-6, IL-8, C3a/C5a Alveolocapillary Membrane Damage Exudative edema, fibrin, surfactant inactivation Consolidation + Impaired Gas Exchange V/Q mismatch, hypoxemia, fever, productive cough INNATE IMMUNITY TISSUE INJURY
2

Diagnostic Protocol

Suspect community-acquired pneumonia in any patient presenting with acute-onset cough (productive or dry), fever or hypothermia, dyspnea, and pleuritic chest pain, particularly when accompanied by focal auscultatory findings such as crackles, bronchial breath sounds, or egophony. Physical examination findings alone are insufficient for diagnosis; a chest radiograph demonstrating a new pulmonary infiltrate is required to confirm the diagnosis and distinguish pneumonia from acute bronchitis, heart failure exacerbation, or pulmonary embolism. Once the diagnosis is confirmed, the immediate clinical priority is severity assessment using a validated scoring system to determine site of care, because this single decision has the greatest impact on both cost and patient outcomes.

Severity Scoring: CURB-65

CURB-65 severity score for community-acquired pneumonia risk stratification
ScoreCriteria Met30-Day MortalityRecommended Site of Care
0No CURB-65 criteria present0.6%Outpatient treatment
1One criterion (most commonly age ≥65)2.7%Outpatient; consider brief observation
2Two criteria present6.8%Hospital admission (short-stay or general ward)
3Three criteria present14.0%Hospital admission; assess for ICU
4–5Four or five criteria present27.8%Hospital admission; assess for ICU using the ATS/IDSA severity criteria (Step 3)

CURB-65 components: Confusion (new-onset, AMT score ≤8), Urea >7 mmol/L (>20 mg/dL), Respiratory rate ≥30/min, Blood pressure (SBP <90 or DBP ≤60 mmHg), Age ≥65. Each criterion scores one point (total range 0–5). The PSI/PORT score is an alternative 20-variable model that incorporates demographics, comorbidities, vital signs, and laboratory values to stratify patients into five risk classes (I through V). Risk Class I–II patients (mortality <1%) are safely managed as outpatients, Class III (mortality 0.9–2.8%) may be considered for brief observation, and Class IV–V (mortality 8–29%) require inpatient management. CURB-65 is preferred in emergency settings for its simplicity, while PSI/PORT performs better for identifying truly low-risk patients safe for discharge.

Diagnostic Workup

Recommended diagnostic tests with performance characteristics
TestRationale / What It ShowsSensitivitySpecificity
Chest radiograph (PA + lateral)Confirms pneumonia (new infiltrate/consolidation); identifies complications (effusion, cavitation, multi-lobar disease)75–85%85–95%
Sputum Gram stain + cultureIdentifies causative organism and guides targeted therapy; obtain before antibiotics when possible50–60%85–90%
Legionella urinary antigenDetects L. pneumophila serogroup 1 (accounts for 80% of Legionella CAP); rapid turnaround (<1 hour)70–80%99%
Pneumococcal urinary antigenDetects S. pneumoniae C-polysaccharide; remains positive despite prior antibiotics; useful when sputum unavailable65–80%90–97%
Blood cultures (2 sets)Identify bacteremia (positive in 5–14% of hospitalized CAP); essential for severe CAP and ICU patients5–14%>99%
Procalcitonin (PCT)PCT >0.25 ng/mL supports bacterial etiology; serial levels guide antibiotic duration (stop when <0.25 or ≥80% decline from peak)78%83%

Differential Diagnosis

Key conditions to exclude when evaluating suspected pneumonia
ConditionDistinguishing FeatureKey Workup
Acute decompensated heart failureBilateral perihilar vascular congestion (butterfly pattern), elevated JVP, peripheral edema, B-lines on lung ultrasound; BNP >400 pg/mLBNP/NT-proBNP, echocardiogram, CXR showing cardiomegaly + cephalization
Pulmonary embolismSudden-onset pleuritic chest pain and dyspnea without productive cough; risk factors for DVT; hypoxemia disproportionate to CXR findings; Hampton hump or Westermark signD-dimer, CT pulmonary angiography, Wells score
Lung abscessSubacute presentation with foul-smelling sputum, history of aspiration risk (alcoholism, seizures, dysphagia); CXR shows thick-walled cavitary lesion with air-fluid levelCT chest with contrast, sputum for anaerobic culture, bronchoscopy if non-resolving
Acute exacerbation of COPDIncreased baseline dyspnea and sputum volume/purulence without new infiltrate on imaging; diffuse wheezing rather than focal crackles; no fever or low-grade onlyCXR (no consolidation), spirometry if stable, sputum culture for purulent exacerbation
TuberculosisChronic cough >3 weeks, night sweats, weight loss; upper lobe cavitary lesion; epidemiologic risk (endemic area, immunosuppression, incarceration)AFB smear and culture (3 sputum specimens), IGRA or PPD, CXR upper lobe infiltrate
3

Treatment Algorithm

The overarching goal of CAP treatment is rapid eradication of the causative pathogen, prevention of complications such as empyema and bacteremia, and early transition from parenteral to oral therapy. Empiric antibiotic selection is stratified by site of care and patient comorbidities, with regimens designed to cover both typical and atypical organisms. Administer the first antibiotic dose within 4 hours of presentation (ideally within 1 hour for severe CAP), as delays beyond this window are associated with increased mortality. De-escalation from broad-spectrum to targeted therapy should occur as soon as microbiologic data allow, typically by 48–72 hours. Total treatment duration for uncomplicated CAP is 5–7 days, guided by clinical response and procalcitonin kinetics. Grade A

1
Step 1 — Outpatient (CURB-65 0–1, No Comorbidities)

Healthy outpatients without chronic heart, lung, liver, or renal disease and no antibiotic use in the prior 90 days can be managed with monotherapy targeting the most common typical pathogen (S. pneumoniae). Expected clinical improvement within 48–72 hours. Grade A

Amoxicillin: Amoxicillin 1 g PO TID × 5–7 days

Alternative (penicillin allergy or atypical coverage): Doxycycline 100 mg PO BID × 5–7 days

Outpatient with comorbidities (COPD, diabetes, heart failure, alcoholism, or antibiotic use in prior 90 days): add macrolide for atypical coverage or use respiratory fluoroquinolone monotherapy. Grade B

Combination: Amoxicillin-clavulanate 875/125 mg PO BID × 5–7 days plus Azithromycin 500 mg PO day 1, then 250 mg PO daily × 4 days

ResponderDefervescence and improving symptoms within 48–72 hours. Complete 5-day course if afebrile for at least 48 hours and clinically stable at day 5.
Non-ResponderPersistent fever or worsening after 72 hours of outpatient therapy. Obtain chest imaging and consider hospital admission. Proceed to Step 2.
2
Step 2 — Inpatient, Non-Severe CAP

Hospitalized patients with non-severe CAP require IV antibiotics with dual coverage of typical and atypical organisms. The preferred regimen combines a beta-lactam with a macrolide. Respiratory fluoroquinolone monotherapy is an acceptable alternative when beta-lactam allergy or macrolide intolerance precludes combination therapy. Target transition from IV to oral antibiotics within 48–72 hours once clinical stability criteria are met. Grade A

Preferred: Ceftriaxone 1–2 g IV daily plus Azithromycin 500 mg IV/PO daily

Alternative beta-lactam: Ampicillin-sulbactam 3 g IV q6h plus azithromycin

Fluoroquinolone monotherapy: Levofloxacin 750 mg PO/IV daily × 5 days or Moxifloxacin 400 mg PO daily × 5 days

MRSA or Pseudomonas risk in non-severe CAP: after prior respiratory isolation of MRSA or P. aeruginosa, add coverage for that pathogen and obtain cultures (and a nasal PCR for MRSA) to allow de-escalation. After recent hospitalization and receipt of parenteral antibiotics in the last 90 days, obtain cultures but withhold MRSA or Pseudomonas coverage unless culture results are positive; if a rapid MRSA nasal PCR is available, withhold MRSA coverage when it is negative and add coverage when it is positive.

ResponderSwitch IV to oral when afebrile ≥24 hours, HR <100, RR <24, SBP ≥90, SpO2 >90% on room air, and able to take oral medications. Complete 5–7 day total course.
Non-ResponderClinical deterioration or no improvement at 72 hours. Obtain CT chest, consider bronchoscopy with BAL. Reassess for empyema, lung abscess, or resistant organism. Escalate to Step 3.
3
Step 3 — Severe CAP / ICU (ATS/IDSA Criteria: 1 Major or ≥3 Minor)

ICU-level care is indicated when major criteria are met: invasive mechanical ventilation or vasopressor requirement. Minor criteria include respiratory rate ≥30, PaO2/FiO2 ratio ≤250, multi-lobar infiltrates, confusion, BUN >20 mg/dL, leukopenia (WBC <4,000), thrombocytopenia (platelets <100,000), hypothermia (<36 C), and hypotension requiring aggressive fluid resuscitation. Three or more minor criteria also warrant ICU admission. Cover MRSA or Pseudomonas empirically only when a risk factor for that pathogen is present: prior respiratory isolation of MRSA or P. aeruginosa, or recent hospitalization and receipt of parenteral antibiotics in the last 90 days (the guideline calls for validating these risk factors with local data). In severe CAP with such a risk factor, add coverage for that pathogen and obtain cultures (and a nasal PCR for MRSA) to allow de-escalation if cultures are negative and the patient is improving. For non-severe inpatients, follow Step 2: after prior respiratory isolation of that pathogen, add coverage and obtain cultures; after recent hospitalization and receipt of parenteral antibiotics, obtain cultures and withhold coverage unless culture results are positive (for MRSA, withhold coverage if a rapid nasal PCR is negative and add it if the PCR is positive). Grade A

Standard ICU: Ceftriaxone 2 g IV daily plus Azithromycin 500 mg IV daily

If MRSA risk: add Vancomycin AUC-guided dosing (target AUC 400–600 mg·h/L) or Linezolid 600 mg IV/PO q12h

If Pseudomonas risk: substitute Piperacillin-tazobactam 4.5 g IV q8h (extended infusion over 4h) or Cefepime 2 g IV q8h for ceftriaxone, plus azithromycin

ResponderDe-escalate to targeted therapy based on culture results. Transition to oral step-down as clinically stable. Total course 7 days (may extend to 14 days for Pseudomonas or MRSA bacteremia).
Non-ResponderConsider CT-guided drainage for empyema, surgical decortication for organized empyema, or ECMO for refractory ARDS. Broaden antifungal or antiviral coverage if immunocompromised.
11
NNT
Atypical coverage preventing treatment failure
6
NNT
Early antibiotics reducing mortality (severe CAP)
50
NNH
C. difficile from fluoroquinolone exposure
250
NNH
QTc prolongation requiring drug cessation
Absolute Contraindication
Known anaphylaxis to penicillins or cephalosporins precludes all beta-lactam agents. For outpatients with comorbidities and for inpatients with non-severe CAP, use respiratory fluoroquinolone monotherapy (levofloxacin or moxifloxacin) as the alternative regimen. In severe CAP, the 2019 ATS/IDSA guideline does not recommend fluoroquinolone monotherapy as empiric therapy, and both of its severe-CAP regimens (a beta-lactam plus a macrolide or a beta-lactam plus a respiratory fluoroquinolone) contain a beta-lactam, so neither applies to a patient with beta-lactam anaphylaxis; the guideline names no regimen for that case. NICE NG250, which grades severity by clinical judgment together with the CURB65 score, lists levofloxacin as the alternative antibiotic for high-severity CAP with penicillin allergy, advises consulting a local microbiologist if a fluoroquinolone is not appropriate, and refers to MHRA advice to avoid coadministration of a corticosteroid with a fluoroquinolone. Avoid azithromycin monotherapy for inpatients due to inadequate pneumococcal coverage.
Relative Contraindication
Fluoroquinolones should be avoided in patients with history of tendinopathy, aortic aneurysm, myasthenia gravis, or QTc >500 ms. For patients on concurrent QTc-prolonging agents (amiodarone, ondansetron), substitute doxycycline for azithromycin or use a beta-lactam plus doxycycline combination instead.

Special Populations

Dose adjustments and drug selection for special populations
PopulationDrug / ConsiderationSpecific Recommendation
Renal ImpairmentLevofloxacinCrCl 20–49 mL/min: 750 mg IV/PO q48h. CrCl <20 mL/min or hemodialysis: 500 mg IV/PO q48h. No dose adjustment needed for ceftriaxone or azithromycin.
Hepatic ImpairmentMoxifloxacin, azithromycinAvoid moxifloxacin in Child-Pugh C (hepatotoxicity risk, no dose adjustment available). Use azithromycin with caution in Child-Pugh B–C; monitor LFTs weekly. Ceftriaxone: reduce dose if combined hepatic + renal impairment.
Elderly (≥65)FluoroquinolonesIncreased risk of tendon rupture (6-fold in patients >60), C. difficile infection, and QTc prolongation. Prefer beta-lactam plus macrolide over fluoroquinolone when possible. Assess renal function with Cockcroft-Gault; adjust levofloxacin accordingly.
PregnancyBeta-lactams preferredAmoxicillin and ceftriaxone are considered safe across all trimesters. AVOID fluoroquinolones (cartilage toxicity risk) and doxycycline (dental/bone effects after 16 weeks). Azithromycin is acceptable for atypical coverage.
PediatricAmoxicillin, ceftriaxoneAmoxicillin 90 mg/kg/day PO divided TID (max 3 g/day) for outpatient. Ceftriaxone 50–100 mg/kg IV daily (max 2 g) for inpatient. Add azithromycin 10 mg/kg day 1 (max 500 mg), then 5 mg/kg daily × 4 days for atypical coverage in children ≥5 years.
Aspiration RiskAmpicillin-sulbactamAdd anaerobic coverage with ampicillin-sulbactam 3 g IV q6h or amoxicillin-clavulanate for outpatients. Consider metronidazole 500 mg IV/PO q8h as add-on if lung abscess suspected. Avoid clindamycin as first-line due to rising anaerobic resistance.

Drug Interactions

Clinically significant interactions requiring action
DrugInteracting AgentMechanismClinical EffectManagement
AzithromycinAmiodarone, sotalol, ondansetronAdditive QTc prolongation via delayed cardiac repolarization (IKr channel blockade)Risk of torsades de pointes, sudden cardiac deathCheck baseline ECG and QTc. If QTc >500 ms, substitute doxycycline for azithromycin. Monitor telemetry in hospitalized patients on concurrent QTc-prolonging drugs.
LevofloxacinOral divalent/trivalent cations (Al, Mg, Ca, Fe, Zn)Chelation of fluoroquinolone by metal cations in GI tract, reducing oral bioavailability by 50–90%Subtherapeutic antibiotic levels, treatment failureAdminister levofloxacin 2 hours before or 6 hours after antacids, sucralfate, iron supplements, or multivitamins containing metals.
LevofloxacinWarfarinCYP1A2 inhibition reduces warfarin S-isomer metabolism; displacement from albumin bindingINR elevation (1.5–3-fold increase), bleeding riskCheck INR within 3–5 days of starting fluoroquinolone. Reduce warfarin dose by 25–33% empirically. Consider using ceftriaxone plus azithromycin instead to avoid interaction.
CeftriaxoneCalcium-containing IV solutions (Ringer’s lactate)Ceftriaxone-calcium precipitation forms insoluble particulates in tubing and potentially in vivoFatal pulmonary/renal microemboli in neonates; risk theoretical in adultsNever co-infuse ceftriaxone with calcium-containing solutions through the same line. In neonates, contraindicated within 48 hours of calcium administration. In adults, flush line between infusions.
Patient Summary

Community-acquired pneumonia is a lung infection that causes cough, fever, and difficulty breathing. Your doctor will determine how sick you are using a scoring system and decide whether you can be treated at home with oral antibiotics or need to be admitted to the hospital for intravenous medications. Most people start feeling better within 2–3 days. The full course of antibiotics is typically 5–7 days. It is important to complete the entire prescribed course even if you feel better, and to return for follow-up if symptoms worsen or do not improve after 3 days.

Treatment by site of care

Adult CAP: empiric antibiotic regimens

Non-pregnant, normal renal function.

Outpatient, no comorbidities

Management

  • Amoxicillin 1 g PO TID; or doxycycline 100 mg PO BID for penicillin allergy or atypical coverage
  • Macrolide alone only if local pneumococcal macrolide resistance <25%

Outpatient with comorbidities

Management

  • Amoxicillin-clavulanate 875/125 mg PO BID plus azithromycin 500 mg day 1, then 250 mg daily × 4 days
  • Or respiratory fluoroquinolone monotherapy

Inpatient, non-severe CAP

Management

  • Ceftriaxone 1–2 g IV daily plus azithromycin 500 mg IV/PO daily
  • Beta-lactam allergy or macrolide intolerance: levofloxacin 750 mg PO/IV daily or moxifloxacin 400 mg PO daily, alone
  • Only risk recent hospitalization plus parenteral antibiotics: cover MRSA or Pseudomonas only if cultures or MRSA nasal PCR are positive

Severe CAP: 1 major or ≥3 minor ATS/IDSA criteria

Management

  • Ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily
  • MRSA risk: add vancomycin (AUC-guided, target 400–600 mg·h/L) or linezolid 600 mg IV/PO q12h
  • Pseudomonas risk: piperacillin-tazobactam or cefepime in place of ceftriaxone, plus azithromycin

Cover MRSA or Pseudomonas only with a risk factor for that pathogen: prior respiratory isolation, or hospitalization plus parenteral antibiotics in the last 90 days.

No improvement by 72 hours: reassess the diagnosis; look for empyema, lung abscess or a resistant organism.

Regimens by site of care and severity. Sources: This article (Treatment Algorithm); ATS/IDSA CAP guideline, 2019
4

Monitoring & Surveillance

Monitoring in CAP serves two concurrent goals: assessing response to empiric therapy and detecting complications that require intervention. The critical inflection point occurs at 48–72 hours after initiating antibiotics, when the majority of patients with appropriate coverage should demonstrate initial clinical improvement including defervescence, declining heart rate, and stabilizing respiratory parameters. Failure to improve at this juncture demands reassessment of the diagnosis, antibiotic coverage adequacy, and evaluation for complications such as parapneumonic effusion, empyema, or lung abscess. Serial procalcitonin measurements offer an objective biomarker-guided approach to antibiotic duration, allowing safe early discontinuation when levels fall below 0.25 ng/mL or decrease by 80% or more from the peak value. For hospitalized patients, daily assessment of clinical stability criteria guides the decision to transition from intravenous to oral therapy and determines readiness for hospital discharge.

Admission / Baseline
  • CBC with differential (WBC, neutrophil count)
  • BMP: BUN, creatinine, electrolytes, glucose
  • Procalcitonin level (baseline for trending)
  • CRP (optional; correlates with severity)
  • Arterial blood gas or SpO2 on room air
  • Blood cultures (2 sets) before antibiotics
48–72 Hours
  • Clinical stability assessment (T, HR, RR, BP, SpO2)
  • Repeat procalcitonin (assess for ≥80% decline)
  • Review microbiologic data; de-escalate therapy
  • Assess IV-to-oral transition eligibility
Day 5–7 (End of Therapy)
  • Procalcitonin if using to guide discontinuation (<0.25 ng/mL target)
  • Confirm afebrile ≥48 hours and ≤1 sign of instability
  • Assess for discharge readiness (oral tolerance, stable vitals, adequate home support)
6–8 Weeks Post-Discharge
  • Follow-up chest radiograph (especially age >50 or smokers) to confirm radiographic resolution
  • Evaluate for underlying malignancy if non-resolving infiltrate
  • Assess smoking cessation, pneumococcal/influenza vaccination status

Response & Safety Parameters

Monitoring protocol: parameters, targets, and action thresholds
ParameterTarget / ThresholdFrequencyAction if Abnormal
Temperature<37.8 °C for ≥24 consecutive hoursEvery 4–8 hoursPersistent fever at 72 hours: obtain CT chest, reassess coverage, check for empyema or abscess
Procalcitonin<0.25 ng/mL or ≥80% decline from peakBaseline, 48–72h, day of planned discontinuationIf PCT remains elevated or rising: extend therapy, repeat cultures, consider resistant organism or non-infectious diagnosis
Oxygen saturationSpO2 >90% on room air (or >88% if COPD)Continuous or every 4 hoursWorsening hypoxemia despite 48h therapy: escalate to high-flow nasal cannula or NIV; ICU transfer if PaO2/FiO2 <200
WBC countTrending toward normalization (4,500–11,000/microL)Baseline and every 48–72 hoursPersistent leukocytosis (>15,000) or new leukopenia (<4,000) at 72 hours: broaden coverage, obtain CT, consider bone marrow suppression or overwhelming sepsis
Renal function (Cr, BUN)Stable or improving from baselineEvery 24–48 hours if on vancomycin; otherwise baseline and PRNRising creatinine: assess volume status, hold nephrotoxins, adjust vancomycin per AUC-guided protocol. Vancomycin AUC target 400–600 mg·h/L.
5

Clinical Commentary

Clinical Pearl
Procalcitonin kinetics are more informative than a single absolute value. A PCT level that is declining by 80% from peak reliably signals adequate antibiotic effect even if the absolute number remains above 0.25 ng/mL. Conversely, a plateau or secondary rise in PCT after initial decline should prompt investigation for treatment failure, nosocomial superinfection, or empyema formation. Serial PCT-guided protocols reduce antibiotic duration by an average of 2–3 days without increasing adverse outcomes, directly decreasing Clostridioides difficile risk and antibiotic resistance pressure.
Clinical Pearl
The most reliable bedside sign of lobar consolidation is egophony (the “E-to-A” change), which has a positive likelihood ratio of 4.1 for pneumonia when present, substantially higher than crackles (LR+ 2.0) or bronchial breath sounds (LR+ 3.3). However, egophony is insensitive (sensitivity only 4–16%) and absence does not exclude pneumonia. In the era of point-of-care lung ultrasound, bedside detection of dynamic air bronchograms within a consolidated lobe has sensitivity exceeding 90% for pneumonia and can be performed faster than a portable chest radiograph, making it invaluable in the critically ill patient too unstable for transport.
Common Pitfall
Routinely extending antibiotic therapy beyond 5–7 days for uncomplicated CAP remains one of the most common errors in clinical practice. Clinicians often continue antibiotics until the chest radiograph clears, but radiographic resolution lags behind clinical improvement by weeks to months, particularly in elderly patients and those with COPD. Extending antibiotics beyond clinical resolution does not hasten radiographic clearing but does increase rates of C. difficile infection, drug-related adverse effects, and antimicrobial resistance. Use clinical stability criteria (afebrile 48 hours plus no more than one sign of instability) and procalcitonin trends rather than imaging to guide discontinuation.
Common Pitfall
Prescribing a respiratory fluoroquinolone (levofloxacin or moxifloxacin) as empiric monotherapy for every hospitalized CAP patient is a stewardship failure with real consequences. While effective, fluoroquinolones carry FDA black box warnings for tendon rupture, peripheral neuropathy, and CNS effects, and they are potent drivers of C. difficile and multidrug-resistant organism selection. Reserve fluoroquinolone monotherapy for non-severe CAP in patients with genuine beta-lactam allergy (IgE-mediated anaphylaxis, not GI intolerance) or documented macrolide allergy; the 2019 ATS/IDSA guideline does not recommend it as empiric therapy for severe CAP (for severe CAP when no beta-lactam can be used, see the Absolute Contraindication box). For most inpatients, ceftriaxone plus azithromycin provides equivalent efficacy with a narrower resistance footprint.
Black Box Warning / High-Alert Drug
Fluoroquinolones (levofloxacin, moxifloxacin, ciprofloxacin): FDA black box warning for disabling and potentially irreversible adverse reactions including tendinitis and tendon rupture (especially Achilles), peripheral neuropathy (numbness, tingling, burning pain in extremities), and central nervous system effects (seizures, confusion, hallucinations, depression, suicidal ideation). Risk is increased in patients over age 60, those taking concurrent corticosteroids, and organ transplant recipients. Additionally, fluoroquinolones are associated with aortic aneurysm and dissection. Discontinue immediately at the first sign of tendon pain, swelling, or neuropathic symptoms. Prefer beta-lactam plus macrolide regimens when fluoroquinolones are not specifically required.
When to Refer
ICU transfer criteria: Need for invasive mechanical ventilation or vasopressor support (norepinephrine) to maintain MAP ≥65 mmHg. Also consider ICU for patients meeting ≥3 ATS/IDSA minor severity criteria (RR ≥30, PaO2/FiO2 ≤250, multilobar infiltrates, confusion, BUN >20, WBC <4,000, platelets <100,000, hypothermia <36 °C, hypotension requiring aggressive fluids).

Pulmonology consultation: Non-resolving pneumonia (persistent infiltrate at 6–8 weeks despite appropriate therapy) requires bronchoscopy with BAL to evaluate for endobronchial obstruction (malignancy), unusual organisms (fungal, mycobacterial), or organizing pneumonia.

Thoracic surgery / interventional radiology: Parapneumonic effusion with pH <7.20 or positive fluid culture (empyema) requires chest tube drainage or video-assisted thoracoscopic surgery (VATS) decortication. Lung abscess >6 cm failing 4–6 weeks of IV antibiotics may need CT-guided percutaneous drainage.

Infectious disease consultation: Isolation of MRSA, Pseudomonas, or other multidrug-resistant organisms; failure of two empiric regimens; or immunocompromised host with atypical pathogens (Pneumocystis, CMV, invasive aspergillosis).
Areas of Uncertainty
  • Optimal role of corticosteroids as adjunctive therapy in severe CAP remains debated; some trials show reduced time to clinical stability, but benefit in non-ICU patients is unclear
  • Whether macrolide immunomodulatory effects (anti-inflammatory beyond antimicrobial) contribute independently to improved outcomes in CAP is not definitively established
  • The threshold for adding anti-MRSA and anti-Pseudomonal coverage lacks validated prediction tools; current guidance relies on risk factor assessment rather than prospective scoring systems

Practice Insights: Lessons From the Bedside

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across emergency medicine, inpatient medicine, and infectious disease services, community-acquired pneumonia is the field where the 2019 ATS/IDSA guideline retirement of the HCAP category plus the 2023 CAPE-COD trial (Dequin et al., NEJM 2023) supporting hydrocortisone in severe CAP plus shorter antibiotic duration evidence has substantially reshaped management. The clearest outcome gains fall to severe CAP patients in the ICU receiving hydrocortisone per CAPE-COD evidence and to outpatient CAP patients no longer receiving macrolide monotherapy in regions with high pneumococcal macrolide resistance.

What the Guideline Misses

The 2023 CAPE-COD trial (Dequin et al., NEJM 2023) demonstrated that hydrocortisone 200 mg/day by continuous IV infusion for 4 or 7 days, as determined by clinical improvement, followed by tapering for a total of 8 or 14 days, reduced 28-day mortality in adults admitted to the ICU for severe CAP (6.2% vs 11.9% with placebo; absolute difference, 5.6 percentage points). The 2019 ATS/IDSA guidelines predate this evidence; they recommend not routinely using corticosteroids in adults with nonsevere CAP and suggest not routinely using them in adults with severe CAP, but the field has shifted toward selective hydrocortisone in severe ICU CAP. CAPE-COD required at least one severity criterion: a Pneumonia Severity Index above 130, mechanical ventilation (invasive or noninvasive) with PEEP of 5 cm H2O or more, high-flow oxygen with FiO2 of 50% or more and a PaO2/FiO2 ratio below 300, or a partial rebreathing mask with a reservoir bag and a PaO2 below a flow-dependent threshold. Its exclusions included vasopressor treatment for septic shock at inclusion, a clinical history suggesting aspiration of gastric content, a positive rapid influenza PCR, active tuberculosis or fungal infection, active viral hepatitis or active infection with herpes viruses, and myelosuppression; for severe influenza pneumonia, the 2019 ATS/IDSA guideline suggests not routinely using corticosteroids.

Patterns That Recur

Macrolide monotherapy (azithromycin or clarithromycin) for outpatient CAP in regions where Streptococcus pneumoniae macrolide resistance exceeds 25% is the practice gap that recurs most often. The 2019 ATS/IDSA guidelines recommend amoxicillin or doxycycline as outpatient first-line where local resistance is high, with macrolide reserved for low-resistance regions. Local antibiogram review at the practice level should drive empiric selection, and routine deferral to “azithromycin Z-pack” produces preventable treatment failures.

A Bedside Heuristic

CURB-65 score plus clinical judgment for site-of-care decisions, rather than any single severity tool in isolation. CURB-65 ≤1 generally outpatient (~3% mortality), ≥2 admission consideration (~10% mortality), ≥3 admission (~22% mortality), with the need for ICU care judged by the ATS/IDSA severity criteria rather than by the score, because CURB-65 was not designed to select the level of care for a hospitalized patient. PSI/PORT is more granular but logistically less practical for ED-level decisions. Social factors (homelessness, drug use, ability to obtain oral medications) override the score when they preclude reliable outpatient management.

The Duration Doctrine

Total antibiotic duration of 5 days for uncomplicated CAP per multiple trials supporting non-inferiority of shorter courses, with extension only when complications (bacteremia, empyema, abscess) or non-typical pathogens (Legionella, Pseudomonas, MRSA) warrant. IV-to-PO switch when afebrile + clinically improving + tolerating oral intake + hemodynamically stable — typically by day 3 of hospitalization. The historical 7-10 day “complete the course” duration is unnecessarily long in most uncomplicated CAP.

Illustrative Scenario

A man in his late sixties presented to the emergency department with 3 days of productive cough, fever to 38.9°C, and progressive dyspnea on exertion. Chest X-ray showed right lower lobe consolidation, and laboratory studies revealed WBC 18,400 with left shift, BUN 32 mg/dL, lactate 1.8, and SpO2 91% on room air. CURB-65 score was 2 (BUN over 19 + age over 65). He was admitted to the inpatient medicine ward on ceftriaxone 1 g IV daily plus azithromycin 500 mg IV daily as combination empiric coverage, plus rapid influenza testing which returned positive for influenza A. Oseltamivir 75 mg twice daily was added for 5 days. He demonstrated clinical improvement by hospital day 3 — afebrile for 24 hours, decreased oxygen requirement, tolerating oral intake — and he was transitioned to oral levofloxacin 750 mg daily, with planned total antibiotic duration 5 days from initial dose. He was discharged on hospital day 4 with completion of antibiotics, oseltamivir, and outpatient follow-up at 4 weeks for chest X-ray to document resolution. He had no readmission and recovered fully.

The takeaway: CURB-65-driven admission decision plus appropriate combination empiric coverage plus influenza testing with empiric oseltamivir during season plus IV-to-PO switch at clinical improvement plus 5-day total duration is the modern uncomplicated CAP pathway. The historical 7-10 day prolonged IV antibiotic approach is unnecessary in most patients.

Protocol Adjustments to the Standard Pathway

  1. Hydrocortisone 200 mg/day by continuous IV infusion for 4 or 7 days (as determined by clinical improvement), followed by tapering for a total of 8 or 14 days, started no longer than 24 hours after the first severity criterion, in ICU patients with severe CAP who meet the CAPE-COD enrollment criteria (criteria listed under What the Guideline Misses above; the trial excluded patients with a positive rapid influenza PCR, patients receiving vasopressors for septic shock at inclusion, patients with a clinical history suggesting aspiration of gastric content, and patients with active tuberculosis or fungal infection, active viral hepatitis or active infection with herpes viruses, or myelosuppression, and the 2019 ATS/IDSA guideline suggests not routinely using corticosteroids in adults with severe influenza pneumonia) per CAPE-COD 2023 trial (Dequin et al., NEJM 2023) demonstrating a 5.6-percentage-point absolute reduction in 28-day mortality (6.2% vs 11.9% with placebo). The 2019 ATS/IDSA guidelines predate this evidence; selective hydrocortisone in patients who meet these criteria is current best practice.
  2. Outpatient CAP: amoxicillin or doxycycline where local S. pneumoniae macrolide resistance >25%, not macrolide monotherapy. Local antibiogram review at the practice level drives empiric selection; routine “Z-pack” produces preventable treatment failures in high-resistance regions.
  3. CURB-65 + clinical judgment for site of care: ≤1 outpatient, ≥2 admission; the need for ICU care is judged by the ATS/IDSA severity criteria, not by the CURB-65 score. Social factors (homelessness, drug use, oral medication access) override score when they preclude reliable outpatient management.
  4. Total 5-day antibiotic duration for uncomplicated CAP per non-inferiority evidence, with extension only for complications or non-typical pathogens. IV-to-PO switch when afebrile + clinically improving + tolerating PO + hemodynamically stable — typically by day 3.

CAPE‑COD criteria

Hydrocortisone in severe CAP

Adults in ICU for severe CAP with at least one of:

  • PSI >130, or ventilation (invasive or NIV) with PEEP ≥5 cm H₂O
  • High-flow O₂: FiO₂ ≥50% and PaO₂/FiO₂ <300
  • Partial rebreathing mask with reservoir bag and PaO₂ below a flow-dependent cutoff

Not studied in CAPE‑COD, e.g.:

  • Vasopressors for septic shock at inclusion
  • History suggesting aspiration of gastric content
  • Positive rapid influenza PCR

Hydrocortisone 200 mg/day IV

  • 4 or 7 days, as determined by clinical improvement, then taper: 8 or 14 days in total
  • CAPE‑COD 28‑day mortality: 6.2% vs 11.9% with placebo

Severe influenza pneumonia: 2019 ATS/IDSA suggests not routinely using corticosteroids.

Nonsevere CAP: 2019 ATS/IDSA recommends not routinely using corticosteroids.

CAPE‑COD at a glance. Sources: This article; Dequin et al., NEJM 2023; ATS/IDSA 2019
6

Frequently Asked Questions

When should I switch from IV to oral antibiotics in hospitalized CAP patients?
Transition from IV to oral antibiotics once the patient demonstrates clinical stability: temperature below 37.8 degrees Celsius for at least 24 hours, heart rate under 100 bpm, respiratory rate below 24 breaths per minute, systolic blood pressure at or above 90 mmHg, oxygen saturation above 90% on room air, and the ability to tolerate oral intake. Most patients meeting these criteria can switch within 48 to 72 hours. Early IV-to-oral conversion reduces hospital length of stay without increasing treatment failure or mortality.
How do I differentiate typical from atypical CAP at the bedside, and does it change empiric therapy?
Classic typical pneumonia presents with abrupt onset of high fever, rigors, productive cough with purulent or rust-colored sputum, and lobar consolidation on chest radiograph. Atypical pneumonia tends toward gradual onset with dry cough, low-grade fever, extrapulmonary symptoms such as headache or myalgia, and diffuse interstitial or patchy infiltrates. However, significant clinical overlap exists, and no bedside feature reliably distinguishes them. Current guidelines recommend empiric regimens that cover both typical and atypical organisms for all hospitalized patients, making precise pathogen-based distinction less critical for initial management.
What is the optimal duration of antibiotic therapy for uncomplicated CAP?
For uncomplicated CAP, a minimum of 5 days of antibiotic therapy is recommended, provided the patient has been afebrile for at least 48 hours and demonstrates no more than one sign of clinical instability before discontinuation. Extending treatment beyond 5 to 7 days does not improve outcomes for most patients and increases the risk of adverse effects including Clostridioides difficile infection. Procalcitonin-guided discontinuation can further support shorter courses: consider stopping antibiotics when procalcitonin drops below 0.25 ng/mL or decreases by 80 percent or more from peak.
gomdori Medical — Community-Acquired Pneumonia — Diagnosis and Evidence-Based Treatment
Last updated: 2026-04-04 gomdorimedical.com
Related clinical topics
More in Infectious Diseases
  • Pneumocystis Jirovecii Pneumonia: Diagnosis, Treatment, and Prophylaxis
  • Clostridioides difficile Infection — Diagnosis and Targeted Treatment
  • Whipple Disease: Diagnosis, Antibiotic Treatment, and Long-Term Management
  • Syphilis: Diagnosis, Staging, and Treatment Management
  • Legionella Pneumonia: ATS/IDSA Diagnosis with Urinary Antigen Testing and Levofloxacin or Azithromycin Therapy
  • Clostridioides difficile Infection: Diagnosis, Risk Stratification, and Fidaxomicin-First Treatment
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

  • ATS/IDSA 2019 Guideline: Community-acquired Pneumonia in Adults (American Journal of Respiratory and Critical Care Medicine · 2019)
Posted in Infectious DiseasesTagged antibiotic stewardship, atypical pneumonia, CAP treatment, community-acquired pneumonia, CURB-65 score, empiric antibiotics, pneumococcal pneumonia, pneumonia diagnosis, PSI PORT score, respiratory infection

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

61 free tools

Endoscopy Findings Atlas · Explore endoscopic findings and diagnostic distinctions.

Health & clinical tools

Find personal records, research helpers and clinical references.

  • Personal Records & Visits11 tools
  • Measurements & Conversions3 tools
  • Research & Events11 tools
  • Clinical Scores & Tests16 tools
  • Medication & Treatment References14 tools
  • Screening & Procedures6 tools
Browse all 61 tools →

Clinical references are for qualified professionals. Check each tool’s scope and limitations.

Tools to try
  • AUDIT-C Alcohol Screening & Unit Calculator
  • Acute Pancreatitis Severity Calculator
  • Ascites SAAG & SBP Diagnostic Assistant
Support This Project
Help keep medical education free
Donate via PayPal

Recent Posts

  • Recurrent Pericarditis: Colchicine, Rilonacept, Anakinra, and Steroid-Sparing IL-1 Blockade
  • Charles Bonnet Syndrome: Visual Release Hallucinations in Acquired Vision Loss Reassurance and Cognitive Coping Strategies
  • PCOS Endocrine Workup: Rotterdam Criteria, Hyperandrogenism Differential, and Long-Term Metabolic Surveillance
  • Crohn’s Disease — Diagnosis, Montreal Classification, and Therapy
  • PAPA Syndrome: PSTPIP1 Autoinflammatory Disease with Pyogenic Sterile Arthritis Pyoderma Gangrenosum and Cystic Acne

Categories

  • Allergy & Clinical Immunology
  • Cardiovascular Medicine
  • Clinical Nutrition
  • Clinical Pharmacology
  • Critical Care Medicine
  • Dermatology
  • Emergency Medicine
  • Endocrinology & Metabolism
  • Gastroenterology
  • General Surgery
  • Geriatric Medicine
  • Hematology & Blood Disorders
  • Infectious Diseases
  • Medical Genetics
  • Nephrology & Renal Care
  • Neurology
  • Obstetrics & Gynecology
  • Occupational & Environmental Medicine
  • Oncology & Cancer Care
  • Ophthalmology
  • Order Sets
  • Orthopedics & Sports Medicine
  • Otolaryngology
  • Pain Medicine
  • Palliative Care
  • Pediatrics
  • Procedures
  • Psychiatry
  • Radiology
  • Respiratory Medicine
  • Rheumatology
  • Sleep Medicine
  • Urology
  • Vaccines & Preventive Medicine

Medical Disclaimer

This content is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for clinical decision-making. The author assumes no liability for actions taken based on this content.

GM

Gomdori, MD

Gastroenterologist · Medical educator

A practising gastroenterologist in South Korea writing bedside-focused clinical education — guideline-derived, dose-precise, and aimed at the decision in front of you rather than the exam question.

Writes about

Gastroenterology & hepatologyEndoscopyGuideline appraisal

Editorial standard

  • Every figure is traced to a primary source and dated
  • Corrections are made on request — not quietly
  • Unverifiable data is omitted, never estimated
About the author Corrections

gomdori Medical

Evidence-based medical education by a practicing gastroenterologist in South Korea. Free clinical content for physicians, residents, and medical students.

Learn more →

Quick Links

  • Gastroenterology
  • Procedures
  • Critical Care
  • About
  • Medical Disclaimer

Contact

Corrections, topic requests, and feedback are always welcome.

gomdoridoctor@gmail.com

Support via PayPal

© 2026 gomdori Medical. All rights reserved.

Content is for educational purposes only and does not constitute medical advice. Full disclaimer

Built with clinical expertise & programmatic precision.

AboutToolsPrivacy PolicyTerms of UseEditorial PolicyDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

AboutToolsPrivacy PolicyTerms of UseDisclaimerContact
Free tools →

© 2026 Gomdori Medical. Educational content only — not professional advice. Figures are dated at the point of publication and change over time; verify against the original source before acting on them.

Copyright © 2026 Gomdori Medical – OnePress theme by FameThemes